Gene

EGFR

epidermal growth factor receptor

Explore in graph →CI-GENE-00044375HGNC:3236 ENSG00000146648 NCBI 1956 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (644)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 251–300 of 644 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR H773_V774insH2
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Does Not Support Sensitivity Response	3

Cohorts

Alteration frequency by cohort (195)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved195 cohort rows (showing 45, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Endometrial Cancer (MSK, Cancer Discovery 2023) ucec_ancestry_cds_msk_2023	Endometrial Carcinoma	Ssm

Literature

Linked publications (141)

25 per page, newest first.

pubmedPublishedShowing 26–50 of 141 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.
· Onco Targets Ther · 2014 · PMID 24729716 · validated civic_curation pubmed
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
· Clin Cancer Res · 2006 · PMID 16818686 · validated civic_curation pubmed
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.
· J Clin Oncol · 2007 · PMID 17538160 · validated civic_curation pubmed
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

EGFR K467T3
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	3	accepted	EID1083 In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumum… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC	civic
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	submitted	EID7087 Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC) PMID 29196463 · Strickler et al., 2018 · Open in CIViC	civic
Futuximab/Modotuximab Mixture + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1082 In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumum… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC	civic

EGFR K708R3
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID9641 Ba/F3 cells transfected with EGFR K708R had levels of p-EGFR, p-STAT5, and p-AKT that were similar to known activating mutation L858R and higher than in cells expressing wild-type EGFR. PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	3	submitted	EID9649 The oncogenic potential of somatic EGFR mutations found in colorectal cancer samples were tested. IL-3 independent growth of Ba/F3 cells was achieved when cells were transduced with EGFR K708R. NIH-3T… (full text at CIViC) PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID9659 Oncogenic somatic EGFR mutations found in colorectal cancer samples were tested for sensitivity to EGFR inhibitors cetuximab and panitumumab. Ba/F3 cells expressing EGFR K708R showed a dose-dependent … (full text at CIViC) PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic

EGFR L718Q4
Afatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID8071 Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with afatinib suppressed EGFR phosphorylation of L858R+L797S, and caused complete inhibition… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic
Erlotinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	submitted	EID8075 Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with erlotinib suppressed phosphorylation of EGFR L858R+C797S and to a lesser extent EGFR L8… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic
Erlotinib + OsimertinibCombination	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID8081 A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. A set of osimertinib resistant tumours were treated with 25mg/kg osimertinib and 2… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic
Osimertinib	Lung Adenocarcinoma	Predictive	D	Supports Resistance	4	submitted	EID8058 A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic

EGFR L718Q + EGFR L718V2
Afatinib	Lung Adenocarcinoma	Predictive	C	Does Not Support Resistance	3	submitted	EID8054 A 62 year old patient with 4 pack-year smoking history with back and flank pain was found to have metastatic lung adenocarcinoma by CT and MRI. Targeted NGS sequencing discovered an EGFR L858R mutatio… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic
Osimertinib	Lung Adenocarcinoma	Predictive	C	Supports Resistance	4	submitted	EID8052 A 62 year old patient with 4 pack-year smoking history with back and flank pain was found to have metastatic lung adenocarcinoma by CT and MRI. Targeted NGS sequencing discovered an EGFR L858R mutatio… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic

EGFR L718V3
Afatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID8074 Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with afatinib suppressed EGFR phosphorylation of L858R+L797S, and caused complete inhibition… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic
Erlotinib	Lung Adenocarcinoma	Predictive	D	Supports Resistance	2	submitted	EID8069 Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with erlotinib suppressed phosphorylation of EGFR L858R+C797S but did not decrease phosphory… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic
Osimertinib	Lung Adenocarcinoma	Predictive	D	Supports Resistance	3	submitted	EID8059 A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic

EGFR L747_P753>Q2
Afatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID2599 In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID2600 A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC	civic